SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Advisorshares Trust - AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF

AdvisorShares Pure US Cannabis ETF is seeing heightened engagement driven by Trulieves historic NYSE uplisting and broader anticipation for the DEAs upcoming rescheduling hearings. Investors are actively debating the impact of these milestones on sector-wide institutional capital access and the structural advantages of holding underlying MSO stocks versus the ETF.

Green Thumb Industries, Inc. engages in the manufacture and distribution of branded cannabis products. Its brands include RYTHM, Dogwalkers, Beboe, Good Green, Doctor Solomon’s, and &Shine. It operates through the Retail and Consumer Packaged Goods segments. The Retail segment focuses on retailing cannabis to patients and consumers. The Consumer Packaged Goods segment refers to the cultivation, production, and sale of cannabis products to retail stores. The company was founded by Benjamin Kovler and Max Cohen on February 18, 2002 and is headquartered in Chicago, IL.

Green Thumb Industries Inc - Ordinary Shares (Sub Voting)

Green Thumb Industries

Green Thumb Industries is trending as investors aggressively debate its strong balance sheet, profitability, and active share buyback program while anticipating potential federal reclassification and uplisting catalysts. The community is actively comparing it against peers, with many bulls viewing current price levels as an undervalued entry point for a long-term play on US cannabis reform.

Trulieve Cannabis Corp. engages in the cultivation, processing, manufacturing, and retail distribution of medical and adult-use cannabis products. It cultivates and produces its products in-house and distributes to its branded stores, as well as directly to patients via home delivery. The company was founded by Kim Rivers & Jason Pernell on September 17, 1940 and is headquartered in Tallahassee, FL.

Trulieve Cannabis Corp - Ordinary Shares (Sub Voting)

Trulieve Cannabis

Trulieve Cannabis is seeing heightened interest as investors anticipate its historic move from the OTC markets to the NYSE, with the company's CEO set to ring the opening bell. Community discussion is focused on the strategic advantage of this uplisting, which is expected to catalyze institutional inflows and set a new standard for U.S.-based cannabis operators.

Oscar Health, Inc. is a healthcare insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending as institutional investors and the community closely watch its breakout momentum and upcoming earnings, with active discussions focusing on management's reaffirmed guidance, record membership growth, and potential margin expansion. Community sentiment is divided between excitement over the stock's recent strong performance and technical setup, and cautionary concerns regarding future regulatory risks and historical price volatility.

Senseonics Holdings, Inc. is a medical technology company, which engages in the development and manufacture of glucose monitoring products. Its primary product is the brand Eversense CGM (continuous glucose monitoring) including sensors, smart transmitters, and mobile applications. The company was founded on June 26, 2014 and is headquartered in Germantown, MD.

Senseonics Holdings Inc

Senseonics is trending following a 80 million dollar stock offering that triggered significant dilution concerns and downward price pressure. Investors are actively debating the company's long-term capital management, leadership performance, and the risk of further share price volatility.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apple is experiencing significant volatility and a sharp pullback from recent highs following the announcement of its new AI strategy, 'Apple Intelligence,' and a Siri overhaul at WWDC. The community is actively debating whether the stock's elevated valuation is justified given the perceived lack of innovation, while traders are focused on the classic 'sell the news' pattern and the reliance on third-party cloud infrastructure.

Invesco DB US Dollar Index Bullish Fund - Invesco DB US Dollar Index Bullish Fund

Invesco DB US Dollar Index Bullish Fund

The Invesco DB US Dollar Index Bullish Fund (UUP) is trending as traders closely watch its strength as a macro indicator for tightening financial conditions and global risk asset volatility. The community is actively discussing the funds role as a safe-haven play and its inverse relationship with precious metals and mining equities amid ongoing geopolitical tensions and interest rate policy uncertainty.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending as investors debate the impact of prediction markets on its core sportsbook business, with many in the community closely monitoring the upcoming World Cup as a critical engagement catalyst. Sentiment remains heavily divided, featuring vocal disagreements over the company's long-term growth potential and executive management decisions.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 2017 and is headquartered in Leander, TX.

Firefly Aerospace Inc.

Firefly Aerospace is trending as traders rotate capital into space-related stocks ahead of the highly anticipated SpaceX IPO, while recent NASA contracts and expansion news fuel bullish sentiment regarding the company's long-term infrastructure role. Investors are closely debating the impact of a recent equity offering versus the stock's potential for rapid valuation re-rating within the surging commercial space sector.

PayPal Holdings, Inc. engages in the development of technology platforms that enable digital payments and simplifies commerce experiences on behalf of merchants and consumers worldwide. Its solutions include PayPal, PayPal Credit, Braintree, Venmo, Xoom, and Paydiant products. The firm also enables consumers to exchange funds with merchants using funding sources, which include bank account, PayPal account balance, PayPal Credit account, credit, and debit card or other stored value products. It operates through United States and Other Countries geographical segments. The company was founded in December 1998 and is headquartered in San Jose, CA.

PayPal Holdings Inc

PayPal is currently trending as investors debate whether the stock is an undervalued cash-generating machine or a long-term value trap amid concerns over stagnant growth and intense competition. While community sentiment is heavily polarized, much of the conversation centers on the company's aggressive share buyback program, new AI-driven cost-cutting initiatives, and a recent partnership announcement with Tencent to expand its reach into the Chinese market.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Here's Why Sagimet Biosciences Inc. (SGMT) Could be Great Choice for a Bottom Fisher

After losing some value lately, a hammer chart pattern has been formed for Sagimet Biosciences Inc. (SGMT), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Wall Street Analysts Believe Sagimet Biosciences Inc. (SGMT) Could Rally 298.5%: Here's is How to Trade

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 298.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Sagimet Biosciences Inc. (SGMT) is a Great Momentum Stock: Should You Buy?

Does Sagimet Biosciences Inc. (SGMT) have what it takes to be a top stock pick for momentum investors? Let's find out.

Does Sagimet Biosciences Inc. (SGMT) Have the Potential to Rally 241.77% as Wall Street Analysts Expect?

The mean of analysts' price targets for Sagimet Biosciences Inc. (SGMT) points to a 241.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Canaccord Genuity Group Raises Sagimet Biosciences (NASDAQ:SGMT) Price Target to $49.00

Canaccord Genuity Group raised their target price on Sagimet Biosciences from $28.00 to $49.00 and gave the stock a 'buy' rating in a research note on Monday...

Sagimet Biosciences Targets Acne, Plans U.S. Phase III for Denifanstat After $175M Raise

Sagimet Biosciences (NASDAQ:SGMT) said it is sharpening its strategic focus on developing differentiated therapies for patients with moderate to severe acne, with plans to advance its lead fatty acid...

Guggenheim Lowers Sagimet Biosciences (NASDAQ:SGMT) Price Target to $25.00

Guggenheim cut their target price on Sagimet Biosciences from $27.00 to $25.00 and set a "buy" rating on the stock in a research note on Wednesday...

Why Is Sagimet Biosciences Stock Trading Higher On Monday?

Sagimet shares surge as Phase 3 acne trial plans and $175M offering fund pipeline through 2028, with technicals showing strong momentum.read more...

Why Sagimet Biosciences Stock Is Soaring Today

Key PointsSagimet Biosciences is developing a handful of drugs, but its priority is acne therapies...

Biotech Breakthroughs and Energy Deals Send These Stocks Soaring

A powerful wave of dealmaking, clinical breakthroughs, and infrastructure buildouts is driving renewed momentum with companies spanning energy, biotech, semiconductors, and AI ecosystems delivering headline-making developments. $USEG, $QUIK, $KBLB, $YAAS, $SGMT, $DKI, $GLND

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Current Price	$6.53
Prev Close	$6.76
Open	$6.95
Dividend Yield	0.00%
50-Day Moving Average	$6.68
Beta	0.00
Avg. Volume	930,262.40
PE Ratio	-4.87

52-Week High	$11.41
52-Week Low	$4.50
Market Capitalization	$413.61M
EPS (Annual)	-$1.58
Price to Book	2.08
Revenue Per Employee	$0.00

SGMTSagimet Biosciences Inc

Fundamentals

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest SGMT News